The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide
Overview
- Phase
- Not Applicable
- Intervention
- Placebo
- Conditions
- Type2 Diabetes
- Sponsor
- University Hospital, Gentofte, Copenhagen
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- C-peptide
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This study will investigate if the effect of DPP-4 inhibitors is mediated in part by Glucose-dependent insulinotropic polypeptide.
Detailed Description
A randomized, placebo controlled study. Using a GIP receptor antagonist, we will investigate the glucose lowering effect of GIP during treatment with DPP-4 inhibitors.
Investigators
Signe Stensen
MD
University Hospital, Gentofte, Copenhagen
Eligibility Criteria
Inclusion Criteria
- •type 2 diabetes, treatment: lifestyle changes or metformin
- •HbA1c \< 75 mmol/mol
Exclusion Criteria
- •diagnosed liver disease
- •eGFR \< 60 ml/min/1,73m2
- •NYHA III or IV
Arms & Interventions
Placebo
Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Intervention: Placebo
Placebo
Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Intervention: GIP receptor antagonist
Placebo
Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Intervention: Placebo tablet
DPP-4 inhibitor
DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Intervention: Placebo
DPP-4 inhibitor
DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Intervention: GIP receptor antagonist
DPP-4 inhibitor
DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Intervention: DPP-4 inhibitor
Outcomes
Primary Outcomes
C-peptide
Time Frame: 5 hours
Concentrations of C-peptide during GIP receptor antagonism compared to placebo
Secondary Outcomes
- Total and intact GIP(5 hours)
- Insulin(5 hours)
- Total and intact GLP-1(5 hours)
- CTX(5 hours)
- Plasma glucose(5 hours)
- Glucagon(5 hours)
- Lipids(5 hours)